Fig 1.
Study design and data flow, cohort setting.
A total of 82,898 patients were enrolled during the study period. 255 and 197 patients who met the IC-A and B were extracted, respectively. Patients selected for IC-C (n = 197) were excluded from the subsequent analyses due to the same number of patients as in IC-B. JMDC; Japan Medical Data Center, ICD-10; Tenth Revision of the International Statistical Classification of Diseases and Related Health Problems, IC; Inclusion criteria, PPV; positive predictive value, NPV; negative predictive value.
Table 1.
Inclusion criteria, and details of the confirmed diagnosis.
Table 2.
Assessment of validity for each cohort.
Fig 2.
Details of medical chart review.
(A) Details of medical chart review for Cohort-A. 83% of cases were confirmed for Crohn’s disease (CD) (confirmed diagnosis at own institution, or another hospital). 7% were considered suspected diagnosis. Cases denied for CD (10%) included infectious enterocolitis (n = 4), intestinal Behçet’s disease (n = 2), drug-induced enterocolitis (n = 1), intestinal tuberculosis (n = 1), unspecified intestinal stenosis (n = 1), and cirrhosis (n = 1). (B) Details of medical chart review for Cohort-B. 97% of cases were confirmed CD. 3% were considered suspected diagnoses. None of the cases were denied CD. *a; Confirmed diagnosis at own institution, b; Diagnosed by an IBD specialist or gastroenterologist in another hospital, c; Diagnosed by a primary care physician (with a description of the findings supporting the diagnosis), d; Diagnosed by a primary care physician (without a description of the findings supporting the diagnosis), CD; Crohn’s disease.
Table 3.
Baseline characteristics of each cohort.
Table 4.
Inter- and intra-rater reliability of the medical chart review.